牛牛AI助理已提取核心訊息
Austin Che has filed an amendment with the Securities and Exchange Commission, disclosing a 5.6% ownership stake in Ginkgo Bioworks Holdings, Inc. This Schedule 13G/A filing, dated December 31, 2023, indicates that Che has sole voting and dispositive power over 95,898,483 shares of the company's Class A Common Stock. The filing details the composition of the shares, including those held directly by Che, as well as those held through various trusts. The shares of Class B Common Stock, which Che holds, can be converted to Class A shares on a one-to-one basis. The filing, completed on February 14, 2024, asserts that the acquisition of these shares is not intended to change or influence the control of Ginkgo Bioworks and is not in connection with any transaction with such purpose.
Austin Che has filed an amendment with the Securities and Exchange Commission, disclosing a 5.6% ownership stake in Ginkgo Bioworks Holdings, Inc. This Schedule 13G/A filing, dated December 31, 2023, indicates that Che has sole voting and dispositive power over 95,898,483 shares of the company's Class A Common Stock. The filing details the composition of the shares, including those held directly by Che, as well as those held through various trusts. The shares of Class B Common Stock, which Che holds, can be converted to Class A shares on a one-to-one basis. The filing, completed on February 14, 2024, asserts that the acquisition of these shares is not intended to change or influence the control of Ginkgo Bioworks and is not in connection with any transaction with such purpose.
奧斯汀·切已向美國證券交易委員會提交了一項修正案，披露了Ginkgo Bioworks Holdings, Inc.5.6％的所有權。該附表13G/A於2023年12月31日提交的文件顯示，車對該公司A類普通股的95,898,483股擁有唯一的投票權和處置權。該文件詳細說明了股票的構成，包括Che直接持有的股票以及通過各種信託持有的股份。Che持有的B類普通股可以一對一地轉換爲A類股票。該文件於2024年2月14日完成，聲稱收購這些股份無意改變或影響銀杏生物工程的控制權，也與任何以此類目的的交易無關。
奧斯汀·切已向美國證券交易委員會提交了一項修正案，披露了Ginkgo Bioworks Holdings, Inc.5.6％的所有權。該附表13G/A於2023年12月31日提交的文件顯示，車對該公司A類普通股的95,898,483股擁有唯一的投票權和處置權。該文件詳細說明了股票的構成，包括Che直接持有的股票以及通過各種信託持有的股份。Che持有的B類普通股可以一對一地轉換爲A類股票。該文件於2024年2月14日完成，聲稱收購這些股份無意改變或影響銀杏生物工程的控制權，也與任何以此類目的的交易無關。
有用
沒用